Teladoc, Inc. (the "Company") announced today that J.P. Morgan Securities LLC and Deutsche Bank Securities Inc., the lead book-running managers in the Company's recent public sale of 9,487,500 shares of common stock, are releasing a lock-up restriction with respect to 119,991 shares of the Company's common stock held by an officer of the Company. The release will take effect on September 24, 2015, and the shares may be sold on or after such date. All other lock-up restrictions applicable to holders of the Company's common stock expire 180 days after such recent public sale. This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended. About Teladoc Teladoc, Inc. (NYSE: TDOC) is the nation's first and largest telehealth platform, delivering on-demand health care anytime, from almost anywhere via mobile devices, the internet, secure video and phone. More than 12.5 million U.S. members are connected to Teladoc's network of over 1,500 board-certified, state-licensed physicians and behavioral health professionals who provide care for a wide range of non-emergency conditions. With a median response time of less than 10 minutes, Teladoc physicians will perform more than 525,000 telehealth visits in 2015. Teladoc and its physicians consistently earn a 95 percent member satisfaction rating or better, and Teladoc is the only telehealth company to be certified by the National Committee for Quality Assurance (NCQA) for its physician credentialing process. Recognized by MIT Technology Review as one of its " 50 Smartest Companies 2015," Teladoc works with health plans, employers, organizations and individuals to provide access to affordable, high-quality health care on demand. Teladoc is transforming the access, cost and quality dynamics of health care delivery. For more information, visit please teladoc.com, twitter.com/teladoc, facebook.com/teladoc or linkedin.com/teladoc.